8-K: Curium to Acquire Lantheus in $8 Billion Merger

Curium and Lantheus Holdings, Inc. have entered into a definitive agreement for Curium to acquire Lantheus in a cash and stock deal valued at up to $8 billion.

Summary

• Lantheus Holdings, Inc. has entered into a definitive Agreement and Plan of Merger with Curium US Holdings LLC, a subsidiary of Curium.
• The transaction is valued at up to $114.50 per share for Lantheus shareholders, totaling approximately $8.0 billion.
• This includes $102.50 per share in cash at closing and up to $12.00 per share in non-transferable Contingent Value Rights (CVRs).
• The CVRs are tied to the achievement of specified commercial milestones for Lantheus's product portfolio through 2030.
• The combined company will offer a comprehensive radiopharmaceutical portfolio spanning diagnostics and therapeutics across more than 70 countries.
• The transaction is expected to close in the first half of 2027, subject to customary closing conditions, including shareholder and regulatory approvals.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive development, indicating a significant premium acquisition that validates the company's market position and future potential.

Positives

• Significant premium offered to Lantheus shareholders: 38% to the 60-day VWAP and 29% to the 30-day VWAP as of May 21, 2026.
• Provides near-term certain value of $102.50 per share in cash at closing.
• Contingent Value Rights (CVRs) offer potential for up to an additional $12.00 per share, allowing shareholders to participate in future commercial success.
• The combination creates a leading radiopharmaceutical company with a broad portfolio across diagnostics and therapeutics.
• The combined entity will have a global reach, serving patients in over 70 countries.
• Lantheus's Board of Directors unanimously approved the transaction, deeming it the best path to maximize shareholder value.
• Curium's strong global manufacturing platform and theranostics expertise complement Lantheus's radiodiagnostics business.

Negatives

• The transaction is subject to shareholder approval and regulatory approvals, which could delay or prevent closing.
• The CVRs are contingent on achieving specific sales milestones, and there is no guarantee these payments will be made.
• The announcement and pendency of the acquisition may disrupt Lantheus's business operations and management focus.
• Lantheus will suspend its previously issued FY 2026 guidance due to the pending transaction.

Risks

• Uncertainties regarding the timing of the proposed acquisition and satisfaction of closing conditions, including regulatory approvals and shareholder vote.
• Potential for competing offers or acquisition proposals.
• Risk that CVR milestones may not be achieved, resulting in no additional payments to shareholders.
• Disruption to Lantheus's business, including supplier and partner relationships, due to the announcement and pendency of the acquisition.
• Diversion of management time and attention from ongoing business operations.
• Potential for stockholder litigation related to the acquisition.
• Curium's ability to obtain financing for the acquisition and successfully integrate Lantheus post-closing.
• Continued market expansion, penetration, and reimbursement for Lantheus's key products like PYLARIFY, DEFINITY, and Neuraceq in a competitive landscape.

Future Outlook

The merger is expected to close in the first half of 2027. Lantheus will continue to operate independently until then. Lantheus has suspended its FY 2026 guidance due to the pending transaction and will not host a conference call for its Q2 2026 results.

Management Comments

• "Lantheus is the ideal partner to accelerate what we have been building at Curium... Lantheus complementary business accelerates our strategy with a robust U.S. commercial infrastructure, a complementary F18-isotope based prostate diagnostics franchise and marks our entry in the U.S. market for diagnostic solutions targeting Neurology and Echocardiography."
• "We believe this transaction is the ultimate validation of what the Lantheus team has built over seven decades of innovation in radiopharmaceuticals. Combining strategically with Curium brings together two pioneers with complementary strengths and a shared passion for nuclear medicine."
• "I am tremendously proud of everything our people have achieved, and I am confident this combination is the best path forward for our shareholders, our employees, and the millions of patients we serve."
• "This transaction underlies our ongoing commitment to Curiums growth and emphasizes our strong conviction in the potential of nuclear medicine and the future of the sector."
• "This highly strategic combination will allow the combined company to capitalize on the significant emerging opportunities and, most importantly, will allow us to accelerate bringing life-changing solutions to healthcare professionals and benefit millions of patients (and their families) around the world."

Industry Context

StockSavvy.ai notes that this merger signifies a major consolidation trend within the radiopharmaceutical industry, driven by the desire to achieve scale, broaden product portfolios, and enhance global reach in both diagnostics and therapeutics. The combination of Curium's theranostics and global manufacturing with Lantheus's strong U.S. radiodiagnostics business creates a formidable player.

Legal Proceedings

• The filing mentions the risk of stockholder litigation in connection with the proposed acquisition, which may result in significant costs of defense, indemnification, and liability.

Stakeholder Impact

• Shareholders: Receive a significant premium for their shares, with potential for additional upside through CVRs.
• Employees: Potential for integration challenges and changes in roles and responsibilities post-merger; also potential for career growth within a larger entity.
• Customers: Potential for broader access to a combined portfolio of diagnostics and therapeutics, and enhanced global supply chain.
• Suppliers and Business Partners: May experience changes in relationships and operational procedures due to the acquisition.

Next Steps

• Lantheus shareholders will vote on the proposed acquisition.
• Regulatory approvals will be sought.
• Lantheus will continue to operate as an independent company until the transaction closes.
• A preliminary and definitive proxy statement will be filed with the SEC.
• The transaction is expected to close in the first half of 2027.

Key Dates

Recommendation

The acquisition offers a substantial premium and near-term certainty for shareholders. However, the CVRs introduce a speculative element tied to future performance. For existing shareholders, holding the stock allows participation in the potential upside from the CVRs, while also providing a significant cash payout at closing. Investors not wishing to hold CVRs could consider selling at or near the closing price to realize the cash component.

Keywords

Merger Agreement, Radiopharmaceutical, Acquisition, Theranostics, Radiodiagnostics, Contingent Value Rights, Prostate Cancer Diagnostics, Neurology Diagnostics